Literature DB >> 2418860

Interaction of bleomycin, hyperthermia and a calmodulin inhibitor (trifluoperazine) in mouse tumour cells: I. In vitro cytotoxicity.

J Mircheva, P J Smith, N M Bleehen.   

Abstract

Evidence in the literature suggests that hyperthermia (HT) or inhibitors of calmodulin can increase the sensitivity of rodent cells to bleomycin (BLM) by interfering with DNA repair functions. In an attempt to explore methods of improving the efficacy of thermochemotherapy we have investigated the individual and combined effects of HT (44 degrees C) and the calmodulin inhibitor trifluoperazine (TFP, 30 micrograms ml-1) on early plateau phase monolayer cultures of mouse EMT6 tumour cells for simultaneous exposures to BLM. Early plateau phase cultures are relatively resistant both to HT and to BLM. The selected HT and TFP regimens (either alone or in combination) were non-toxic. Comparing the sensitizing effect (given by the ratio: Do BLM/Do BLM + modifier) of the various regimens on BLM-treated cells, we found that: TFP alone had a marginal effect (ratio 1.3), HT alone showed significant potentiation (ratio 19) and the combination of HT and TFP strongly sensitized (ratio greater than 110) cells to BLM cytotoxicity. We propose that the use of calmodulin inhibitors in thermochemotherapy is worthy of further evaluation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2418860      PMCID: PMC2001473          DOI: 10.1038/bjc.1986.14

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Thermal enhancement of DNA strand breakage in mammalian cells treated with bleomycin.

Authors:  R E Meyn; P M Corry; S E Fletcher; M Demetriades
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-09       Impact factor: 7.038

2.  Damage of cellular functions by trifluoperazine, a calmodulin-specific drug.

Authors:  M Osborn; K Weber
Journal:  Exp Cell Res       Date:  1980-12       Impact factor: 3.905

3.  Comparative chemosensitivity of exponential- versus plateau-phase cells in both in vitro model systems.

Authors:  P R Twentyman
Journal:  Cancer Treat Rep       Date:  1976-12

4.  Regulation of intracellular levels of calmodulin and tubulin in normal and transformed cells.

Authors:  J G Chafouleas; R L Pardue; B R Brinkley; J R Dedman; A R Means
Journal:  Proc Natl Acad Sci U S A       Date:  1981-02       Impact factor: 11.205

5.  Similarities in cellular inactivation by hyperthermia or by ethanol.

Authors:  G C Li; E C Shiu; G M Hahn
Journal:  Radiat Res       Date:  1980-05       Impact factor: 2.841

6.  A linear transform of the multi-target survival curve.

Authors:  J V Watson
Journal:  Br J Radiol       Date:  1978-07       Impact factor: 3.039

7.  Ethanol-induced cell sensitization to bleomycin cytotoxicity and the inhibition of recovery from potentially lethal damage.

Authors:  S Mizuno
Journal:  Cancer Res       Date:  1981-10       Impact factor: 12.701

8.  Synergistic enhancement of bleomycin cytotoxicity toward tumor cells in culture by a combination of ethanol and moderate hyperthermia.

Authors:  A Ishida; S Mizuno
Journal:  Gan       Date:  1981-06

9.  Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation.

Authors:  G M Hahn; J Braun; I Har-Kedar
Journal:  Proc Natl Acad Sci U S A       Date:  1975-03       Impact factor: 11.205

10.  Interaction of bleomycin, hyperthermia and a calmodulin inhibitor (trifluoperazine) in mouse tumour cells: II. DNA damage, repair and chromatin changes.

Authors:  P J Smith; J Mircheva; N M Bleehen
Journal:  Br J Cancer       Date:  1986-01       Impact factor: 7.640

View more
  2 in total

Review 1.  Potentiation of DNA damage and cytotoxicity by calmodulin antagonists.

Authors:  S A Rosenthal; W N Hait
Journal:  Yale J Biol Med       Date:  1988 Jan-Feb

2.  Interaction of bleomycin, hyperthermia and a calmodulin inhibitor (trifluoperazine) in mouse tumour cells: II. DNA damage, repair and chromatin changes.

Authors:  P J Smith; J Mircheva; N M Bleehen
Journal:  Br J Cancer       Date:  1986-01       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.